Whan In Pharm signs exclusive agreement of introducing the epilepsy treatment ‘Zebinix’
Whan In Pharm(CEO Won-Bum Lee) signed an exclusive license agreement of ‘Zebinix,’ an epilepsy treatment developed by Portuguese Bial(CEO António Portela), in Korea at the headquarters on the 26th.
‘Zebinix,’ a once-daily new drug, is a product that is being sold in the U.S.( Aptiom®) and Europe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
